

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **RETNLB RABBIT PAB**

货号: S216763

产品全名: RETNLB 兔多抗

基因符号 XCP2; FIZZ1; FIZZ2; HXCP2; RELMb; RELMbeta; RELM-beta

UNIPROT ID: Q9BQ08 (Gene Accession - BC113502)

背景: Resistin-like beta is a protein that in humans is encoded by the RETNLB gene. An infusion of either resistin or RELMB in rats rapidly induced severe hepatic but not peripheral insulin resistance. Increases in circulating resistin or RELMB levels markedly stimulated hepatic glucose production despite the presence of fixed physiologic insulin levels. This enhanced rate of glucose output was due to increased flux through glucose-6-phosphatase. The results supported the notion that a novel family of fat- and gut-derived circulating proteins modulates hepatic insulin action.

抗原: Fusion protein of human RETNLB

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 2000-5000

种属反应性: Rabbit 克隆性: Rabbit Polyclonal


亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction, Cancer


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 216763(RETNLB Antibody) at a dilution of 1/20(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 216763(Anti-RETNLB Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffinembedded Human ovarian cancer tissue using 216763(Anti-RETNLB Antibody) at a dilution of 1/20.



In comparision with the IHC on the left, the same paraffin-embedded Human ovarian cancer tissue is first treated with fusion protein and then with D221195(Anti-RETNLB Antibody) at dilution 1/20.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010